Abstract
The growing body of evidence that patients with lung cancer with particular mutations in the gene encoding the epidermal growth factor receptor are more likely to have a better treatment response to gefitinib emphasizes the need for companies to identify the right patients for targeted therapies early in the development process.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. Lessons from the lung for targeted anticancer drugs. Nat Rev Drug Discov 8, 758–759 (2009). https://doi.org/10.1038/nrd3016
Issue Date:
DOI: https://doi.org/10.1038/nrd3016
